Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P, Grandal B, Jochum F, Bihan K, Coussy F, Barraud S, Asselain B, Dumas E, Sebbag C, Hotton J, Spaggiari E, Pierga JY, Savarino R, Laas E, Spano JP, Reyal F, Hamy AS. Gougis P, et al. Among authors: hamy as. JAMA Netw Open. 2023 Oct 2;6(10):e2339934. doi: 10.1001/jamanetworkopen.2023.39934. JAMA Netw Open. 2023. PMID: 37883083 Free PMC article.
A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.
Hamy AS, Bonsang-Kitzis H, Lae M, Moarii M, Sadacca B, Pinheiro A, Galliot M, Abecassis J, Laurent C, Reyal F. Hamy AS, et al. PLoS One. 2016 Dec 22;11(12):e0167397. doi: 10.1371/journal.pone.0167397. eCollection 2016. PLoS One. 2016. PMID: 28005906 Free PMC article.
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY. Giacchetti S, et al. Among authors: hamy as. Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7. Eur J Cancer. 2017. PMID: 28279941 Clinical Trial.
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F. Hamy AS, et al. Breast Cancer Res Treat. 2018 Jun;169(2):295-304. doi: 10.1007/s10549-017-4610-0. Epub 2018 Jan 27. Breast Cancer Res Treat. 2018. PMID: 29374852
COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I. DE Cremoux P, et al. Among authors: hamy as. Anticancer Res. 2018 Mar;38(3):1485-1490. doi: 10.21873/anticanres.12375. Anticancer Res. 2018. PMID: 29491076 Clinical Trial.
93 results